You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 14, 2025

Physiological Effect: Central Nervous System Stimulation


✉ Email this page to a colleague

« Back to Dashboard


Drugs with Physiological Effect: Central Nervous System Stimulation

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Aurobindo Pharma Ltd ACETAMINOPHEN, ASPIRIN AND CAFFEINE acetaminophen; aspirin; caffeine TABLET;ORAL 211695-001 Feb 2, 2022 OTC No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Granules ACETAMINOPHEN, ASPIRIN AND CAFFEINE acetaminophen; aspirin; caffeine TABLET;ORAL 214039-001 Feb 23, 2021 OTC No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Perrigo ACETAMINOPHEN, ASPIRIN AND CAFFEINE acetaminophen; aspirin; caffeine TABLET;ORAL 075794-001 Nov 26, 2001 OTC No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Takeda Pharms Usa ADDERALL XR 10 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-001 Oct 11, 2001 AB1 RX Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Takeda Pharms Usa ADDERALL XR 15 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-006 May 22, 2002 AB1 RX Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 5 of 5 entries

Central Nervous System Stimulation Market Analysis and Financial Projection

The market for central nervous system (CNS) stimulant drugs and related therapies is experiencing dynamic growth, driven by increasing demand for treatments addressing neurological and psychiatric disorders. Below is an analysis of market dynamics and patent trends shaping this sector:


Market Dynamics

Growth Drivers

  • Rising Prevalence of ADHD and Narcolepsy:
    ADHD affects approximately 7% of adults globally (366 million people), driving demand for stimulants like amphetamines and methylphenidate[1][6][7]. Narcolepsy treatment further propels market growth, with CNS stimulants enhancing daytime wakefulness[6].

  • Expanding Applications:
    Stimulants are increasingly used off-label for cognitive enhancement and obesity management. Innovations like SPN-812, a non-stimulant ADHD drug, aim to reduce abuse potential while maintaining efficacy[3][7].

  • Technological Innovations:
    Precision medicine and AI are accelerating drug discovery, while novel delivery systems (e.g., nanoparticles, intranasal delivery) improve bioavailability[5][8]. Digital therapeutics, such as Tivic Health’s vagus nerve stimulator, personalize treatment through adaptive algorithms[10].

  • Emerging Markets:
    Increased healthcare spending in regions like Asia-Pacific and Latin America supports market expansion, with generics improving accessibility post-patent expirations[14].

Market Size and Projections

  • Valuation: The CNS stimulant market ranges from $8.15B (2025) to $42.73B (2026), depending on included segments. Forecasts suggest a 3.89%–8.1% CAGR, influenced by ADHD therapies and neuromodulation devices[1][6][13].
  • Key Segments:
    • Amphetamines dominate due to widespread ADHD use.
    • Non-stimulants (e.g., atomoxetine) are gaining traction for safety[7].

Challenges

  • Abuse Potential: Stimulant misuse remains a regulatory concern, prompting shifts toward non-addictive alternatives[1][3].
  • Generic Competition: Patent expirations (e.g., Copaxone) have spurred generic entries, intensifying price competition[14].

Patent Landscape

Key Innovations

  1. Non-Stimulant Therapies:
    Supernus Pharmaceuticals’ SPN-812, a selective norepinephrine reuptake inhibitor, targets ADHD with reduced addiction risk[3].
  2. Combination Formulations:
    Patents like CA-2840363-A1 combine low-dose methylphenidate with micronutrients (e.g., acetyl L-carnitine) for chronic fatigue[8].
  3. Neuromodulation Devices:
    Over 63% of neuromodulation patents focus on deep brain stimulation (DBS), with Medtronic leading innovation[4][13]. Tivic Health’s vagus nerve stimulator personalizes treatment parameters via AI[10].

Strategic Trends

  • Personalized Medicine:
    Patents increasingly emphasize patient-specific dosing and delivery systems to enhance efficacy[10][13].
  • Digital Integration:
    Collaborations between pharma and tech firms (e.g., Spark Therapeutics and Neurochase) aim to integrate drug delivery with digital monitoring[5].

Geographic and Competitive Focus

  • North America holds ~40% market share, driven by high ADHD prevalence and R&D investment[1][14].
  • Top Players: Bristol Myers Squibb, Roche, and Eli Lilly lead in traditional stimulants, while startups like Tivic Health pioneer device-based solutions[1][10].

Future Outlook

  • Non-Stimulant Therapies: Expected to capture 25% of the ADHD market by 2030, addressing safety concerns[3][7].
  • Neuromodulation Devices: Projected to grow at 10.3% CAGR (2025–2034) as DBS and spinal cord stimulation gain traction[13].
  • Regulatory Shifts: Stricter controls on stimulant prescriptions may accelerate R&D in abuse-deterrent formulations[1][8].

The CNS stimulation sector is poised for transformative growth, balancing traditional pharmaceuticals with cutting-edge technologies. Strategic patenting in non-stimulant drugs and neuromodulation devices will likely define competitive advantages in this evolving landscape.

References

  1. https://www.promarketreports.com/reports/central-nervous-system-stimulant-drugs-market-11878
  2. https://www.lindushealth.com/blog/the-impact-of-cns-stimulants-exploring-their-effects-and-uses
  3. https://ir.supernus.com/news-releases/news-release-details/supernus-announces-issuance-first-use-patents-protecting-spn-812
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC4446106/
  5. https://www.mordorintelligence.com/industry-reports/central-nervous-system-therapeutics-market
  6. https://www.researchnester.com/reports/central-nervous-system-stimulant-drugs-market/5524
  7. https://openstax.org/books/pharmacology/pages/13-5-cns-stimulants-and-nonstimulants
  8. https://pubchem.ncbi.nlm.nih.gov/patent/CA-2840363-A1
  9. https://patents.google.com/patent/US2892753A/en
  10. https://www.biospace.com/press-releases/tivic-health-files-patent-for-optimized-electrical-stimulation-of-the-vagus-nerve
  11. https://pubchem.ncbi.nlm.nih.gov/patent/US8293794
  12. https://patents.google.com/patent/EP0049604A1/en
  13. https://www.expertmarketresearch.com/patent-analysis/neuromodulation-devices-patent-landscape
  14. https://www.skyquestt.com/report/central-nervous-system-treatment-market
  15. https://www.drugpatentwatch.com/p/patent/4927855

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.